重庆医学2013，Vol.42Issue(11)：1240-1242,3.DOI:10.3969/j.issn.1671-8348.2013.11.016
波生坦联合辛伐他汀治疗中重度肺动脉高压的临床研究
Effects of bosentan combined with simvastatin on medium and severe pulmonary arterial hypertension
摘要
Abstract
Objective To observe the effect of the combination treatment of boscntan and simvastatin in medium-severe pulmonary arterial hypcrtcnsion(PAH). Methods 61 patients with PAH were allocated into three groups:a combination of boscntan and simvastatin group,boscntan group and simvastatin group. WHO heart functional classification, right ventricular systolic pressure (RVSP) ,right ventricle diamctcr(RVd) ,Borg dyspnea index(BDI) ,6 minute walk distancc(6MWD) ,Minnesota Living with Heart Failure Qucstionnairc(MLHFQ) scoring and plasma NT-Pro-BNP concentration were recorded at baseline and after 12 weeks under treatment. Results Compared to baseline, RVSP( 62. 16 + 3. 42 vs. 87. 28 + 5. 30),RVd(2. 50 + 0. 33 vs. 2. 83 + 0. 64),BDI(3. 1 + 1. 5 vs. 4. 1 + 1. 2) ,NT-Pro-BNP lcvcl(289. 1 + 50. 7 vs. 399. 7 + 48. 2) and MLHFQ scoring(42. 21+4. 25 vs. 55. 14 + 3. 48)(P< 0. 05) were decreased significantly(P<0. 01) ,6MWD(34O. 72 + 9. 06 vs. 291. 22 + 4. 14) was increased significantly in combination group(P<0. 01) ;combination group had the greater effect in decreasing RVSPC23. 15 + 6. 25 vs. 18. 71+4. 23),RVd(0. 32 + 0. 26 vs. 0. 39 + 0. 28), MLHFQ scoring(15. 11+4. 23 vs. 11. 72 + 5. 12) , NT-Pro-BNP level (104. 35 + 32. 40 vs. 82. 15 + 61. 02) and increasing 6MWDC52. 33 + 3. 15 vs. 37. 82 + 7. 41) (P<0. ODcomparcd with boscntan group(P<0. 05). Conclusion Boscntan combined with simvastatin was more effective for patients with medium-severe PAH than single medicine treatment.关键词
高血压,肺性/波生坦/辛伐他汀Key words
hypertension, pulmonary/ boscntan/ simvastatin引用本文复制引用
壮可,林玲,林俊,黄春涛..波生坦联合辛伐他汀治疗中重度肺动脉高压的临床研究[J].重庆医学,2013,42(11):1240-1242,3.
